Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Targeted therapy development for metastatic esophageal and gastroesophageal junction (GEJ) cancers lags behind other tumor types.
• Current treatment options, including trastuzumab for HER-2 overexpressing tumors, offer limited survival benefits (median 8-12 months).
• Esophageal and GEJ cancers exhibit significant heterogeneity, complicating treatment strategies.

Purpose of the Study:

• To review molecular aberrations driving esophageal cancer.
• To identify and evaluate promising molecular targets for novel therapeutic agents.
• To assess the efficacy of current and emerging targeted therapies.

Main Methods:

• Review of clinical studies on targeted agents for esophageal and GEJ cancer.
• Analysis of molecular targets including epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER-2), vascular endothelial growth factor (VEGF), MET, and fibroblast growth factor receptor (FGFR).
• Examination of immune-based therapies.

Main Results:

• Trastuzumab (anti-HER-2 antibody) is the only approved novel agent, effective only in HER-2 overexpressing tumors.
• Most targeted agents show minimal benefit in molecularly unselected patient cohorts.
• Emerging targets include MET, FGFR, and immunotherapies.

Conclusions:

• Esophageal and GEJ cancers require novel therapeutic strategies beyond current standards of care.
• Targeted therapies demonstrate efficacy primarily in molecularly defined subgroups.
• Future research necessitates a focus on preselected molecular subgroups for collaborative investigation in this heterogeneous disease.